Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

Lancet

Volumn 352, Issue 9131, 1998, Pages 854-865

  Turner, Robert ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN A; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIET THERAPY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK;

EID: 0032511566     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07037-8     Document Type: Article

References (20)

1. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
2. UKPDS Group. UK Prospective Diabetes Study 24: relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years. Ann Intern Med 1998; 128: 165-75.
3. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-67.
4. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72.
5. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993; 16: 621-29.
6. Nolan JJ, Ludvik B, Beersden P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93.
7. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications on patients with adult-onset diabetes: V- evaluation of phenformin therapy. Diabetes 1975; 24 (suppl 1): 65-184.
8. Nattrass M, Alberti KG. Biguanides. Diabetologia 1978; 14: 71-74.
9. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-79.
10. UKPDS Group. UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 1991; 34: 877-90.
11. UKPDS Group. UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes 1995; 44: 1249-58.
12. UKPDS Group. UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-45.
13. Metropolitan Life Insurance Company. Net weight standard for men and women. Statist Bull 1959; 40: 1-4.
14. UKPDS Group. UK Prospective Diabetes Study 28: a randomised trial of efficacy of early addition of metformin in sulphonylurea-treated non-insulin dependent diabetes. Diabetes Care 1998; 21: 87-92.
15. Rothman KJ. Modern epidemiology. Boston: Little, Brown, 1986.
16. Early Breast Cancer Trialists Collaborative Group. Treatment of early breast cancer. Oxford: Oxford University Press, 1990.
17. UKPDS Group. UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994; 11: 534-44.
18. Beisswenger P, Howell S, Touchette A, Lal S, Szwergold B, Rohlf J. Metformin reduces systemic methylgloxal levels in NIDDM. Diabetes 1997; 46 (suppl 1): 74A (abstr).
19. Modan M, Karasik A, Halkin H, et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response: the Israel study of glucose intolerance, obesity and hypertension. Diabetologia 1986; 29: 82-89.
20. Yki-Jarvinen H, Nikkil K, Ryysy L, Tulokas T, Vanamo R, Hekkil M. Comparison of bedtime insulin regimens in NIDDM: metformin prevents insulin-induced weight gain. Diabetologia 1996; 39 (suppl 1): A33 (abstr).